NCT02407678View on ClinicalTrials.gov

REP1 Gene Replacement Therapy for Choroideremia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

July 23, 2021

Study Completion Date

July 23, 2021

Conditions
Choroideremia
Interventions
GENETIC

AAV-mediated REP1 gene replacement

AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection

Trial Locations (2)

EC1V 2PD

Moorfields Eye Hospital NHS Foundation Trust, London

OX3 9DU

Oxford University Hospitals NHS Foundation Trust, Oxford

All Listed Sponsors
collaborator

Moorfields Eye Hospital NHS Foundation Trust

OTHER

collaborator

University College, London

OTHER

lead

University of Oxford

OTHER

NCT02407678 - REP1 Gene Replacement Therapy for Choroideremia | Biotech Hunter | Biotech Hunter